Literature DB >> 32814842

Letter to the Editor: "Association between metformin medication, genetic variation and prostate cancer risk"-genotyping and patient categorizations, do they matter?

Gerard Marshall Raj1, Rama Krishnan2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32814842     DOI： 10.1038/s41391-020-00269-1

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN： 1365-7852            Impact factor:   5.554


× No keyword cloud information.
  10 in total

Review 1.  Repurposing metformin for the prevention of cancer and cancer recurrence.

Authors:  Brandy M Heckman-Stoddard; Andrea DeCensi; Vikrant V Sahasrabuddhe; Leslie G Ford
Journal:  Diabetologia       Date:  2017-08-03       Impact factor: 10.122

2.  L503F variant of carnitine/organic cation transporter 1 efficiently transports metformin and other biguanides.

Authors:  Azusa Futatsugi; Yusuke Masuo; Shiori Kawabata; Noritaka Nakamichi; Yukio Kato
Journal:  J Pharm Pharmacol       Date:  2016-06-28       Impact factor: 3.765

Review 3.  Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2-3) and Implications for Risk Stratification: A Systematic Review.

Authors:  Christopher J Kane; Scott E Eggener; Alan W Shindel; Gerald L Andriole
Journal:  Eur Urol Focus       Date:  2017-03-11

4.  Response to the Letter to the Editor: "Association between metformin medication, genetic variation and prostate cancer risk"-genotyping and patient categorization, do they matter?

Authors:  Min Joon Lee; Robert J Hamilton
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-09-21       Impact factor: 5.554

Review 5.  Transporters Involved in Metformin Pharmacokinetics and Treatment Response.

Authors:  Xiaomin Liang; Kathleen M Giacomini
Journal:  J Pharm Sci       Date:  2017-05-08       Impact factor: 3.534

6.  Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Authors:  James L Mohler; Emmanuel S Antonarakis; Andrew J Armstrong; Anthony V D'Amico; Brian J Davis; Tanya Dorff; James A Eastham; Charles A Enke; Thomas A Farrington; Celestia S Higano; Eric Mark Horwitz; Michael Hurwitz; Joseph E Ippolito; Christopher J Kane; Michael R Kuettel; Joshua M Lang; Jesse McKenney; George Netto; David F Penson; Elizabeth R Plimack; Julio M Pow-Sang; Thomas J Pugh; Sylvia Richey; Mack Roach; Stan Rosenfeld; Edward Schaeffer; Ahmad Shabsigh; Eric J Small; Daniel E Spratt; Sandy Srinivas; Jonathan Tward; Dorothy A Shead; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2019-05-01       Impact factor: 11.908

Review 7.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.

Authors:  Jonathan I Epstein; Lars Egevad; Mahul B Amin; Brett Delahunt; John R Srigley; Peter A Humphrey
Journal:  Am J Surg Pathol       Date:  2016-02       Impact factor: 6.394

Review 8.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours.

Authors:  Peter A Humphrey; Holger Moch; Antonio L Cubilla; Thomas M Ulbright; Victor E Reuter
Journal:  Eur Urol       Date:  2016-03-17       Impact factor: 20.096

9.  Involvement of carnitine/organic cation transporter OCTN1/SLC22A4 in gastrointestinal absorption of metformin.

Authors:  Noritaka Nakamichi; Hiroyo Shima; Satoshi Asano; Takahiro Ishimoto; Tomoko Sugiura; Kazuki Matsubara; Hiroyuki Kusuhara; Yuichi Sugiyama; Yoshimichi Sai; Ken-Ichi Miyamoto; Akira Tsuji; Yukio Kato
Journal:  J Pharm Sci       Date:  2013-05-10       Impact factor: 3.534

Review 10.  Metformin and the gastrointestinal tract.

Authors:  Laura J McCreight; Clifford J Bailey; Ewan R Pearson
Journal:  Diabetologia       Date:  2016-01-16       Impact factor: 10.122
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.